Email lpt.research@nhs.net to find out more about the studies below.
Enroll-HD, Huntington's disease
Enroll-HD is a worldwide observational study open to people with, or at risk of, Huntington’s disease (HD).
Enroll-HD is a worldwide observational study open to people with, or at risk of, Huntington’s disease (HD). It aims to understand the experience of those living with HD and how the disease changes over time. This study has been open in LPT for over 10 years, there are currently 120 participants in this study in the Trust.
PI: Dr Reza Kiani.
R&D Delivery Team: Dawn Freire-Patino, Joy Fellows
GUIDE-HD, Huntington's disease
GUIDE-HD hopes to investigate whether a new talking therapy aimed at reducing anxiety for Huntington’s disease gene carriers could be beneficial.
GUIDE-HD is a randomised controlled feasibility trial to see whether a new talking therapy which aims to reduce anxiety among Huntington’s Disease gene expansion carriers could be beneficial. This study is led by Chief Investigator Dr Maria Dale in LPT and is jointly run with Lancaster University and the EHDN Psychological Interventions and Approaches Working Group. The work is funded by the Jacques and Gloria Gossweiler Foundation.
HealthE-RND, Neurodegeneration and Huntington's disease
HealthE-RND aims to develop an eHealth platform to improve quality of life in people affected by rare diseases.
HealthE-RND aims to develop an eHealth platform to improve quality of life in people affected by rare diseases. Over 3 years the study team aims to develop an eHealth platform and a quality of life questionnaire. The study is currently focusing on Huntington’s disease, to study whether the platform is useful. You can find out more about HealthE-RND here: https://healthe-rnd.eu/
PI: Dr Maria Dale
R&D Delivery Team: Dr Sarah Baillon, Dawn Freire-Patino, Joy Fellows
iMARK-HD, Huntington's disease
iMARK-HD is a study designed to assess changes in the brain as a result of Huntington's Disease using two types of imaging scans, PET and MRI.
iMark-HD is a study looking for an indicator that can give information about the progression of HD by using MRI scans (which observes the structure of the brain) and PET scans (which observes the function of the brain). By observing these indicators, researchers can better understand how the disease develops. This work could potentially lead to further research into early diagnosis and treatments.
PI: Reza Kiani
R&D Delivery Team: Dr Sarah Baillon, Dawn Freire-Patino, Joy Fellows
Later Stage HD Assessments, Huntington's disease
This study aims to develop tools that capture how HD affects the health and well-being of people who have had signs and symptoms for several years
The Later Stage HD Assessments study aims to develop two assessments that can be used to measure critical milestones and events during the later stages of Huntington’s disease (HD). Participants in the LSA study will be both people diagnosed with HD and their companions, who are participants in the Enroll-HD study.
PI: Reza Kiani
R&D Delivery Team: Dr Sarah Baillon, Dawn Freire-Patino, Joy Fellows
The information on this page is correct as of November 2023.